Alligator’s CEO comments on restructuring plan

16 February, 2024

Søren Bregenholt CEO Alligator Bioscience — Søren Bregenholt, CEO Alligator Bioscience

Alligator’s CEO comments on restructuring plan

16 February, 2024

Alligator Bioscience is coming off a high after reaching the primary endpoint in the OPTIMIZE-1 phase II trial with lead candidate mitazalimab. However, together with their year-end report, Alligator announced a restructuring and cost-cutting plan. Alligator’s CEO Søren Bregenholt stopped by the BioStock studio to tells us more.

Watch the interview with Alligator Bioscience‘s CEO Søren Bregenholt below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.